AR023088A1 - Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas. - Google Patents
Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas.Info
- Publication number
- AR023088A1 AR023088A1 ARP000100810A ARP000100810A AR023088A1 AR 023088 A1 AR023088 A1 AR 023088A1 AR P000100810 A ARP000100810 A AR P000100810A AR P000100810 A ARP000100810 A AR P000100810A AR 023088 A1 AR023088 A1 AR 023088A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydration
- formulas
- optionally substituted
- phenyl
- Prior art date
Links
- 230000036571 hydration Effects 0.000 title abstract 4
- 238000006703 hydration reaction Methods 0.000 title abstract 4
- 229930024421 Adenine Natural products 0.000 title abstract 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000643 adenine Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000000638 stimulation Effects 0.000 title abstract 2
- DRTQHJPVMGBUCF-QPXMQEAJSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidine-2,4-dione Chemical compound O=C1NC(=O)C([3H])=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DRTQHJPVMGBUCF-QPXMQEAJSA-N 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 cytidine diphosphates Chemical class 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229940035893 uracil Drugs 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 2
- 229940113082 thymine Drugs 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 abstract 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- DYWBDRKFYPLULC-UHFFFAOYSA-N cyano(nitrosulfonyl)sulfamic acid Chemical compound C(#N)N(S(=O)(=O)[N+](=O)[O-])S(=O)(=O)O DYWBDRKFYPLULC-UHFFFAOYSA-N 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 239000001177 diphosphate Substances 0.000 abstract 1
- 235000011180 diphosphates Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 1
- 229940045145 uridine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12175499P | 1999-02-26 | 1999-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR023088A1 true AR023088A1 (es) | 2002-09-04 |
Family
ID=22398588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100810A AR023088A1 (es) | 1999-02-26 | 2000-02-25 | Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6331529B1 (https=) |
| EP (1) | EP1161246B1 (https=) |
| JP (1) | JP2002537329A (https=) |
| KR (1) | KR20010114214A (https=) |
| AR (1) | AR023088A1 (https=) |
| AT (1) | ATE281837T1 (https=) |
| AU (1) | AU3612600A (https=) |
| BR (1) | BR0008498A (https=) |
| CA (1) | CA2359891A1 (https=) |
| DE (1) | DE60015734D1 (https=) |
| MX (1) | MXPA01008547A (https=) |
| WO (1) | WO2000050024A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319908B1 (en) | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
| US5763447C1 (en) | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
| TW593331B (en) | 1997-07-25 | 2004-06-21 | Inspire Pharmaceuticals Inc | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
| US6872710B2 (en) | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
| WO1999005155A2 (en) | 1997-07-25 | 1999-02-04 | Inspire Pharmaceuticals, Inc. | Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof |
| US6432454B1 (en) * | 1997-12-12 | 2002-08-13 | C. V. Technologies, Inc. | Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| US6624150B2 (en) | 1999-02-26 | 2003-09-23 | Inspire Pharmaceuticals, Inc. | Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| DE60015734D1 (de) | 1999-02-26 | 2004-12-16 | Inspire Pharmaceuticals Durham | Verwendung von dinukleotidtriphosphaten, cytidindiphosphaten und adenindiphosphaten zur herstellung einer pharmazeutischen zubereitung zur förderung der schleimauthydratation |
| US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| JP2003524636A (ja) * | 1999-12-22 | 2003-08-19 | インスパイアー ファーマシューティカルズ，インコーポレイティド | プリン性受容体アゴニストによる胃腸管の処置方法 |
| US6864243B1 (en) | 2000-05-12 | 2005-03-08 | Inspire Pharmaceuticals, Inc. | Method for treating retinal degeneration with purinergic receptor agonists |
| AU2001260643B9 (en) | 2000-05-30 | 2006-10-19 | Merck Sharp & Dohme Corp. | Ectocornea extension promoters |
| US6555675B2 (en) | 2000-08-21 | 2003-04-29 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists |
| US6867199B2 (en) | 2000-08-21 | 2005-03-15 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapeutic use |
| US7132408B2 (en) | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| JP2005508297A (ja) | 2001-06-25 | 2005-03-31 | インスパイアー ファーマシューティカルズ，インコーポレイティド | Ｐ２ｙプリン受容体作用物質による関節潤滑 |
| JP2005532254A (ja) | 2001-11-06 | 2005-10-27 | インスパイアー ファーマシューティカルズ，インコーポレイティド | 炎症性疾患を治療又は予防する方法 |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US7179481B2 (en) * | 2002-09-19 | 2007-02-20 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
| JP2006505585A (ja) * | 2002-10-18 | 2006-02-16 | モリケム メディシンズ， インコーポレイテッド | ランチビオティクスで眼乾燥症を処置する方法 |
| US7056889B2 (en) | 2002-12-16 | 2006-06-06 | Kimberly-Clark, Worldwide, Inc. | Compounds that bind P2Y2 or P2Y1 receptors |
| US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
| JP2007502829A (ja) * | 2003-08-18 | 2007-02-15 | パリオン・サイエンシィズ・インコーポレーテッド | 環状ピラジノイルグアニジンナトリウムチャネルブロッカー |
| WO2005107787A1 (en) * | 2004-05-06 | 2005-11-17 | Molichem Medicines, Inc. | Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions |
| EP1753445A4 (en) * | 2004-05-06 | 2009-05-20 | Molichem Medicines Inc | TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS |
| US7368439B2 (en) * | 2005-06-15 | 2008-05-06 | Bar - Ilan University | Dinucleoside poly(borano)phosphate derivatives and uses thereof |
| US7851456B2 (en) * | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
| US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| KR100870104B1 (ko) * | 2005-11-28 | 2008-11-26 | 주식회사 머젠스 | 안구건조증 치료 및 예방용 조성물 |
| JP5408882B2 (ja) * | 2008-01-23 | 2014-02-05 | ヤマサ醤油株式会社 | 唾液分泌促進剤 |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| SG10201708931XA (en) | 2012-12-17 | 2017-12-28 | Parion Sciences Inc | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| RU2018138195A (ru) | 2012-12-17 | 2018-12-18 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| KR102622656B1 (ko) | 2016-02-18 | 2024-01-10 | 인버사, 인크. | 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 |
| US10946034B2 (en) | 2018-03-27 | 2021-03-16 | Invirsa, Inc. | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4868154A (en) | 1986-02-19 | 1989-09-19 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with melanocyte stimulating hormones |
| US4753945A (en) | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
| US5635160A (en) * | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
| US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| US5789391A (en) * | 1996-07-03 | 1998-08-04 | Inspire Pharmaceuticals, Inc. | Method of treating sinusitis with uridine triphosphates and related compounds |
| US6159952A (en) * | 1996-11-07 | 2000-12-12 | Inspire Pharmaceuticals, Inc. | Method of treating bronchitis with uridine triphosphate and related compounds |
| CN1262556C (zh) | 1997-02-06 | 2006-07-05 | 印斯拜尔药品股份有限公司 | 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用 |
| EP1011688B1 (en) * | 1997-08-29 | 2005-02-02 | The University of North Carolina at Chapel Hill | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
| DE60015734D1 (de) | 1999-02-26 | 2004-12-16 | Inspire Pharmaceuticals Durham | Verwendung von dinukleotidtriphosphaten, cytidindiphosphaten und adenindiphosphaten zur herstellung einer pharmazeutischen zubereitung zur förderung der schleimauthydratation |
-
2000
- 2000-02-25 DE DE60015734T patent/DE60015734D1/de not_active Expired - Lifetime
- 2000-02-25 JP JP2000600636A patent/JP2002537329A/ja active Pending
- 2000-02-25 AR ARP000100810A patent/AR023088A1/es unknown
- 2000-02-25 EP EP00914781A patent/EP1161246B1/en not_active Expired - Lifetime
- 2000-02-25 BR BR0008498-0A patent/BR0008498A/pt not_active Application Discontinuation
- 2000-02-25 WO PCT/US2000/005282 patent/WO2000050024A2/en not_active Ceased
- 2000-02-25 AU AU36126/00A patent/AU3612600A/en not_active Abandoned
- 2000-02-25 KR KR1020017010900A patent/KR20010114214A/ko not_active Withdrawn
- 2000-02-25 US US09/512,867 patent/US6331529B1/en not_active Expired - Fee Related
- 2000-02-25 MX MXPA01008547A patent/MXPA01008547A/es unknown
- 2000-02-25 CA CA002359891A patent/CA2359891A1/en not_active Abandoned
- 2000-02-25 AT AT00914781T patent/ATE281837T1/de not_active IP Right Cessation
-
2001
- 2001-12-03 US US10/005,267 patent/US6436910B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000050024A2 (en) | 2000-08-31 |
| US20020052338A1 (en) | 2002-05-02 |
| DE60015734D1 (de) | 2004-12-16 |
| US6436910B1 (en) | 2002-08-20 |
| ATE281837T1 (de) | 2004-11-15 |
| MXPA01008547A (es) | 2003-06-06 |
| US6331529B1 (en) | 2001-12-18 |
| JP2002537329A (ja) | 2002-11-05 |
| BR0008498A (pt) | 2002-02-05 |
| CA2359891A1 (en) | 2000-08-31 |
| EP1161246A2 (en) | 2001-12-12 |
| WO2000050024A3 (en) | 2001-07-05 |
| KR20010114214A (ko) | 2001-12-31 |
| EP1161246B1 (en) | 2004-11-10 |
| AU3612600A (en) | 2000-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR023088A1 (es) | Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas. | |
| ES2531011T3 (es) | Métodos y composiciones para el tratamiento del virus de la hepatitis C | |
| EA200201291A1 (ru) | Производные пурина | |
| ATE344271T1 (de) | 2'-fluoronukleoside | |
| BR0011705A (pt) | Derivados de purina | |
| AR247213A1 (es) | Preparacion de acido 7-¡(1-carboxi-3-fenilpropil)amino¿-3,4,6,7,8,12b-octahidro-6-oxopirido ¡2,1-a¿ o hexahidro-6-oxo-1h(1,4-tiazino¡3,4-a¿¡2¿-benzazepin-4-carboxilico, agentes hipertensivos. | |
| AR032883A1 (es) | Metodo de tratamiento de flavivirus y pestivirus | |
| PT980377E (pt) | Analogos de nucleosido de pirimidina anti-viral | |
| BRPI0412314A (pt) | derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina | |
| LU91348I2 (fr) | Telbivudine et ses sels pharmaceutiquement acceptables | |
| SK95093A3 (en) | Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b | |
| TR199903025T2 (xx) | 4-Fenilpiperidin bile�imleri. | |
| JP2008523098A5 (https=) | ||
| KR900018125A (ko) | 뉴클레오사이드 동족체류 | |
| MX9302169A (es) | Fenoxialquilisoxazolas de 1,2,4-oxadiazolilo y su uso como agentes antivirales. | |
| ES8500244A1 (es) | "un procedimiento para preparar derivados de pirazinona" | |
| PT775117E (pt) | Analogos de 2-nitroimidazole fluorinados para detectar celulas de tumor hipoxicas | |
| TR200103858T2 (tr) | Hücre yapışmasının önleyicileri olarak ikame edilmiş purin türevleri | |
| TR200102501T2 (tr) | Antiviral nükleozid analoglar. | |
| FI862963A0 (fi) | Substituerade 3-aminosydnoniminer, deras framstaellningsfoerfarande, deras anvaendning och dessa innehaollande farmaceutiska preparat. | |
| DK160308C (da) | Analogifremgangsmaade til fremstilling af 1,2,4-triazolo(4,3-a)quinazolin-5-(4h)-oner eller deres syreadditionssalte | |
| NO872832D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser. | |
| PT84680B (pt) | Processo para a preparacao de derivados de 1,5-benzotiazepina e de composicoes farmaceuticas que os contem | |
| RU97102130A (ru) | 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено[2,3- d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе | |
| ES2103590T3 (es) | Derivados del acido 3-(indol-3-il) propenoico utilizables como antagonistas nmda. |